TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: - Children and adolescents between the ages of 10-16 years. Subjects cannot turn 17 years and 11 months before the end of treatment (52 weeks) - Diagnosis of type 2 diabetes mellitus and treated for at least 30 days with: diet and exercise alone, diet and exercise in combination with metformin monotherapy, diet and exercise in combination with metformin and a stable (Stable is defined as basal insulin adjustments up to 15%) dose of basal insulin, diet and exercise in combination with a stable (Stable is defined as basal insulin adjustments up to 15%) dose of basal insulin - HbA1c: 7.0-11% (inclusive) if diet and exercise treated or 6.5-11% (inclusive) if treated with metformin as monotherapy, basal insulin as monotherapy or metformin and basal insulin in combination - Body mass index (BMI) above 85% percentile of the general age and gender matched population Exclusion Criteria: - Type 1 diabetes - Maturity onset diabetes of the young (MODY) - Use of any antidiabetic agent other than metformin and/or basal insulin within 90 days prior to screening - Recurrent severe hypoglycaemia or hypoglycaemic unawareness as judged by the investigator - History of chronic pancreatitis or idiopathic acute pancreatitis - Any clinically significant disorder, except for conditions associated with type 2 diabetes history which in the investigator's opinion could interfere with results of the trial - Uncontrolled hypertension, treated or untreated above 99th percentile for age and gender in children - Known or suspected abuse of alcohol or drugs/narcotics

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Lira + Met (Type: EXPERIMENTAL): None
- Placebo + Met (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of High Rebound Mattress Toppers on Sleep and Sleep-Related Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults Age 18-65 who are scheduled for a diagnostic sleep study at the Stanford Sleep Clinic for sleep disorders (including but not limited to, insomnia, Sleep Apnea or other sleep disorder symptoms).~Exclusion Criteria:~* Individuals with a history of having difficulty swallowing food or large capsules. We will not be able to enroll individuals with any known or suspected obstructive disease of the gastrointestinal tract including, but not limited to esophageal stricture, diverticulosis and inflammatory bowel disease (IBD), peptic ulcer disease, Crohn's disease, ulcerative colitis, previous gastrointestinal surgery.~* Individuals who are pregnant.~* Individuals who are unable to provide informed consent (i.e. decisionally impaired).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Low rebound mattress toppers (Type: EXPERIMENTAL): sleep with mattress topper during overnight diagnostic sleep study
- High rebound mattress toppers (Type: EXPERIMENTAL): sleep with mattress topper during overnight diagnostic sleep study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antibiotic Prophylaxis for Endoscopic Ultrasound Guided Fine Needle Aspiration of Pancreatic Cystic Lesions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a pancreatic cyst requiring EUS-FNA to complete evaluation.~* Participant is willing and able to give informed consent for participation in the study.~* Age 18 years or older.~* Ability to understand study procedures and to comply with them for the entire length of the study.~Exclusion Criteria:~* Patients with other co-morbidities requiring antibiotic prophylaxis for endoscopic invasive procedures (such as those with cardiac valve prosthesis).~* Cystic lesion of the intestinal wall (foregut or duplication cyst).~* Use of antibiotic treatment for any other indication during the 5 days prior to the procedure.~* Pregnant woman.~* Known allergy/sensitivity to ciprofloxacin.~* Inability or unwillingness of individual or legal guardian/representative to give written informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: EXPERIMENTAL): 1 intravenous dose followed by 1 oral dose each 12 hours (complete 3 days)
- Antibiotic (Type: ACTIVE_COMPARATOR): Ciprofloxacin 400 mg intravenous one dose followed by ciprofloxacin 500 mg oral each 12 hours (complete 3 days)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Oral Niacinamide on Serum Phosphorus Levels in Hemodialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 18 years~2. Capable of giving informed consent~3. Duration of chronic hemodialysis \> 90 days~4. Dose of phosphorus binder(s) stable over previous 2 week period~5. Serum Phosphorus \> 4.9 mg/dL based on most recent laboratory data within 1 month of enrollment~Exclusion Criteria:~1. Pregnancy~2. Known liver disease~3. Active peptic ulcer disease~4. Treatment with carbamazepine~5. Intolerance to niacinamide~6. Current medication regimen including niacin or niacinamide-containing vitamins~7. More than 1 missed hemodialysis session in the last 30 days~8. Planned or expected surgical procedure in the next 4 months~9. Patients in nursing homes or extended care facilities where administration of the study drug may not be appropriately given

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Treated with a statin~* Fasting LDL-C \>=100 mg/dL and triglyceride \<= 400 mg/dL~* High or very high risk of incurring a cardiovascular event~Exclusion Criteria:~* Pregnant or breastfeeding females~* Cardiovascular or cerebrovascular event or procedure within 90 days~* Congestive heart failure NYHA class IV~* Poorly controlled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bococizumab (PF-04950615; RN316) (Type: EXPERIMENTAL): Bococizumab (PF-04950615; RN316)
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: VPD-737 for Treatment of Chronic Pruritus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of chronic pruritus and unresponsive to current therapies~Exclusion Criteria:~* Have chronic liver or renal disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 0.25 mg VPD-737 (Type: EXPERIMENTAL): 0.25 mg of VPD-737 daily by mouth for 42 days
- 1 mg VPD-737 (Type: EXPERIMENTAL): 1 mg VPD-737 taken daily by mouth for 42 days
- 5 mg VPD-737 (Type: EXPERIMENTAL): 5 mg tablets of VPD-737 to be taken daily by mouth for 42 days
- Placebo (Type: PLACEBO_COMPARATOR): placebo tablets to be taken daily by mouth for 42 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. A diagnosis of CFS, as defined by the Center for Disease Control (1988 CDC case definition) \> 12 months (Appendix D).~2. Age Range: \> 18 years old, \< 60 years old.~3. Males or non-pregnant, non-lactating females: Females must be of non-child bearing potential (either post-menopausal for two (2) years or surgically sterile including tubal ligation) or using an effective means of contraception (birth control pills, intrauterine device, diaphragm). Females who are less than two (2) years post-menopausal, those with tubal ligations and those using contraception must have a negative serum pregnancy test within the two (2) weeks prior to the first study medication infusion. Females of child bearing potential agree to use an effective means of contraception from four (4) weeks prior to the baseline pregnancy test until four (4) weeks after the last study medication infusion.~4. A reduced quality of life as determined by a documented KPS of 40 to 60 on three (3) occasions, each at least 14 days apart, during the twelve (12) weeks immediately preceding the start of study drug infusions. The KPS must be rounded in increments of ten (10).~5. Ability to walk (minimum of 20 seconds) on the moving treadmill (grade = 0%; belt speed = 1 mph) on a minimum of two (2) occasions during the twelve (12) weeks immediately preceding study entry.~6. Laboratory documentation (baseline or historical following onset of CFS/ME) of a negative ANA or a negative anti-ds (double-stranded) DNA, a negative Rheumatoid Factor, and an erythrocyte sedimentation rate (ESR).~7. Laboratory documentation that the patient is euthyroid (patients on thyroid replacement therapy must be on a stable dose during the eight (8) week washout period) based on a thyroid profile (T4, T3, TSH, T3 uptake and Free T4 index) performed during baseline.~8. Ability to provide written informed consent indicating awareness of the investigational nature of this study.~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Part 1: Subjects with 5 to 20 clinically typical, visible and discrete AKs on the full balding scalp.~* Part 2: Subjects with 5 to 20 clinically typical, visible and discrete AKs on the full balding scalp~Exclusion Criteria:~* Location of the treatment area~  * within 5 cm of an incompletely healed wound~ * within 5 cm of a suspected basal cell carcinoma (BCC) or squamous cell carcinoma (SCC)~* Prior treatment with ingenol mebutate gel on the treatment area~* Lesions in the treatment areas that have~  * atypical clinical appearance (e.g., hypertrophic, hyperkeratotic or cutaneous horns) and/or~ * recalcitrant disease (e.g., did not respond to cryotherapy on two previous occasions)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: LEO 43204 (Type: OTHER): Open-label, dose escalation, 2 days treatment
- Part 2: LEO 43204 x dose (Type: ACTIVE_COMPARATOR): X dose for 2 days treatment
- Part 2: LEO 43204 Y dose (Type: ACTIVE_COMPARATOR): Y dose for 2 days treatment
- Part 2: Placebo (Type: PLACEBO_COMPARATOR): Placebo for 2 days treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aurinia Renal Response in Active Lupus With Voclosporin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~- Subjects with evidence of active nephritis, defined as follows:~* Kidney biopsy result within 2 years prior to screening indicating Class III, IV-S, IV-G (alone or in combination with Class V), or Class V LN with a doubling or greater increase of UPCR within the last 6 months to a minimum of ≥1.5 mg/mg for Class III/IV or to a minimum of ≥2 mg/mg for Class V at screening. Biopsy results over 6 months prior to screening must be reviewed with a medical monitor to confirm eligibility.~OR~* Kidney biopsy result within 6 months prior to screening indicating Class III, IV-S or IV-G (alone or in combination with Class V) LN with a UPCR of ≥1.5 mg/mg at screening.~OR~* Kidney biopsy result within 6 months prior to screening indicating Class V LN and a UPCR of ≥2 mg/mg at screening.~  * Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline.~Exclusion Criteria:~* Estimated glomerular filtration rate (eGFR) of ≤45 mL/minute at screening.~* Current or medical history of:~  * Congenital or acquired immunodeficiency.~ * In the opinion of the Investigator, clinically significant drug or alcohol abuse within 2 years prior to screening.~ * Malignancy within 5 years of screening, with the exception of basal and squamous cell carcinomas treated by complete excision.~ * Lymphoproliferative disease or previous total lymphoid irradiation.~ * Severe viral infection or known HIV infection.~ * Active tuberculosis (TB), or known history of TB/evidence of old TB if not taking prophylaxis with isoniazid.~* Other known clinically significant active medical conditions, such as:~  * Severe cardiovascular disease, liver dysfunction or chronic obstructive pulmonary disease or asthma requiring oral steroids or any other overlapping autoimmune condition for which the condition or the treatment of the condition may affect the study assessments or outcomes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Voclosporin (Type: EXPERIMENTAL): oral, 23.7 mg twice daily (BID)
- Placebo Oral Capsule (Type: PLACEBO_COMPARATOR): Voclosporin placebo, oral, 3 capsules twice daily (BID)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Preoperative Gabapentin Versus Pregabalin on Shoulder Pain After Laparoscopic Cholecystectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* uncomplicated laparoscopic cholecystectomy~* American Society of Anesthesiologists (ASA) status \< 3~Exclusion Criteria:~* acute cholecystitis~* conversion to open cholecystectomy~* history of epilepsia, psychiatric disorders and cognitive impairment~* Pregnancy and breastfeeding~* allergy to pregabalin and/or gabapentin~* Chronic pain~* Chronic medication by corticosteroids, neuroleptics or non steroidal anti inflammatory drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): Patients receive 2 capsules as placebo 2 hours before anesthesia. The capsules are delivered by the hospital pharmacy.
- pregabalin (Type: EXPERIMENTAL): patients receive 2 capsules of pregabalin (pregabalin 75), two hours before anesthesia.
- gabapentin (Type: EXPERIMENTAL): patients receive 2 capsules of gabapentin (gabapentin 300), two hours before anesthesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multiple Burrhole Therapy With Erythropoietin for Unstable Moyamoya

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥16 years~* Acute neurological presentation with recurrent transient ischemic attacks (TIA) or cerebral infarction within 30 days of symptom onset~* Angiographic findings compatible with the diagnostic criteria for MMD or MMS (unilateral findings, bilateral distal internal carotid artery involvement without Moyamoya vessels, or presence of other causative factors)~* Significant decrease in basal perfusion and reservoir capacity on brain perfusion CT or Brain single photon emission computed tomography with acetazolamide (Diamox®) challenge (D-SPECT)~Exclusion Criteria:~* Definite presence of transdural collateral flow on cerebral angiography.~* Sufficient perfusion status via Willisian, leptomeningeal, or other collateral systems, as evaluated by multimodal imaging methods.~* \> 30 days after symptom onset

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- multiple burrhole therapy and erythropoietin (Type: EXPERIMENTAL): pretreatment with IV erythropoietin for 3 days, 120000IU#3 then multiple burrhole procedure on the hemisphere effected is performed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 65 years~* Have an elevated serum alanine aminotransferase (ALT) between 1.5 and 10 times the upper limit of normal~* Had adequate bone marrow reserve and organ function~* Are not pregnant and are willing to use contraception, if, of childbearing potential~* Are willing and able to comply with the protocol and to give written informed consent~* Other protocol defined inclusion criteria may apply~Exclusion Criteria:~* Clinical evidence of liver cirrhosis or a diagnosis of definite cirrhosis on liver biopsy~* History of liver failure, severe retinopathy, immunologically mediated disease, cancer or epilepsy with a history of inadequately controlled seizures~* Any cause for the liver disease other than chronic hepatitis C~* Evidence of chronic renal impairment, liver cancer, unstable psychiatric disorder, known or ongoing alcohol or drug abuse~* Positive test at screening for Hepatitis B surface antigen, immunoglobulin M Hepatitis B core antibody and human immunodeficiency virus antibody~* Previous systemic treatment for Hepatitis C with an interferon or ribavirin~* Presence of systemic disease that might interfere with subject safety, compliance or evaluation~* Known allergies to acetaminophen, human serum albumin or mannitol;~* Glucocorticosteroids or other immunosuppressive drugs taken within 28 days of starting treatment~* Bearing organ transplants (except cornea)~* Other protocol defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Interferon-beta-1a (Type: EXPERIMENTAL): None
- Ribavarin plus interferon-beta-1a (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of age-related cataract in the study eye~* Scheduled for cataract surgery and lens implant~Exclusion Criteria:~* Diagnosis of ocular surface disease or glaucoma~* Ocular surgery in the past 3 months~* Wearing a corneal contact lens in the study eye

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Sodium Carboxymethylcellulose and Conventional Therapy (Type: EXPERIMENTAL): Sodium carboxymethylcellulose (Refresh Liquigel®) 1 drop in the study eye 4 times a day for 30 days plus conventional therapy of levofloxacin for 7 days post-cataract surgery and prednisolone for 30 days post-cataract surgery each in the study eye up to 4 times a day.
- Conventional Therapy (Type: ACTIVE_COMPARATOR): Conventional therapy of levofloxacin for 7 days post-cataract surgery and prednisolone for 30 days post-cataract surgery each in the study eye up to 4 times a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete